Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.
Targeted Protein Degradation
Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Lead by experts
Click to find out more about the people behind Amphista Therapeutics.
Ian holds an MA and D.Phil. in Chemistry from the University of Oxford where we was also Visiting Professor in the Department of Chemistry
We seek exceptional and visionary scientists to join our team working on a cutting-edge therapeutic modality focused on bringing much needed new medicines to patients with life-changing diseases.
Amphista is searching for innovative, and highly motivated individuals who enjoy teamwork and are comfortable working in a fast-paced entrepreneurial environment.
If you feel that your skills and experience are aligned to the opportunities posted, please e-mail your CV directly to email@example.com, including the position title in the subject line of your email.